Evaluation of the Activity of Triazoles Against Non-fumigatus Aspergillus and Cryptic Aspergillus Species Causing Invasive Infections Tested in the SENTRY Program.

IF 3.8 4区 医学 Q2 IMMUNOLOGY Open Forum Infectious Diseases Pub Date : 2024-11-01 DOI:10.1093/ofid/ofae532
Michael A Pfaller, Cecilia G Carvalhaes, Paul R Rhomberg, Abigail Klauer, Mariana Castanheira
{"title":"Evaluation of the Activity of Triazoles Against Non-<i>fumigatus Aspergillus</i> and Cryptic <i>Aspergillus</i> Species Causing Invasive Infections Tested in the SENTRY Program.","authors":"Michael A Pfaller, Cecilia G Carvalhaes, Paul R Rhomberg, Abigail Klauer, Mariana Castanheira","doi":"10.1093/ofid/ofae532","DOIUrl":null,"url":null,"abstract":"<p><p>The activity of isavuconazole and other triazoles against non-<i>fumigatus</i> (non-AFM) <i>Aspergillus</i> causing invasive aspergillosis was evaluated. A total of 390 non-AFM isolates were collected (1/patient) in 2017-2021 from 41 hospitals. Isolates were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry and/or internal spacer region/β-tubulin sequencing and tested by Clinical and Laboratory Standards Institute (CLSI) broth microdilution. CLSI epidemiological cutoff values were applied, where available. Isavuconazole showed activity against <i>Aspergillus</i> sections <i>Flavi</i> (n <i>=</i> 122; minimum inhibitory concentration [MIC]<sub>50/90</sub>, 0.5/1 mg/L), <i>Terrei</i> (n <i>=</i> 57; MIC<sub>50/90</sub>, 0.5/0.5 mg/L), <i>Nidulantes</i> (n = 34; MIC<sub>50/90</sub>, 0.12/0.25 mg/L), <i>Versicolores</i> (n <i>=</i> 7; MIC<sub>50</sub>, 1 mg/L), and <i>Circumdati</i> (n <i>=</i> 2; MIC range, 0.12-2 mg/L). Similar activity was displayed by other triazoles against those <i>Aspergillus</i> sections. Most of the isolates from <i>Aspergillus</i> sections <i>Fumigati</i> (n <i>=</i> 9), <i>Nigri</i> (n <i>=</i> 146), and <i>Usti</i> (n <i>=</i> 12) exhibited elevated MIC values to isavuconazole (MIC<sub>50/90</sub>, 2/-, 2/4, and 2/8 mg/L), voriconazole (MIC<sub>50/90</sub>, 2/-, 1/2, and 4/8 mg/L), itraconazole (MIC<sub>50/90</sub>, 2/-, 2/4, and 8/>8 mg/L), and posaconazole (MIC<sub>50/90</sub>, 0.5/-, 0.5/1, and >8/>8 mg/L), respectively. Isavuconazole was active (MIC values, ≤1 mg/L) against <i>Aspergillus parasiticus</i>, <i>Aspergillus tamarii</i>, <i>Aspergillus nomius</i>, <i>Aspergillus nidulans</i>, <i>Aspergillus unguis</i>, <i>Aspergillus terreus</i>, <i>Aspergillus alabamensis</i>, and <i>Aspergillus hortai</i>, while isavuconazole MIC values between 2 and 8 mg/L were observed against cryptic isolates from <i>Aspergillus</i> section <i>Fumigati</i>. Isavuconazole inhibited 96.1% of <i>Aspergillus niger</i> and 80.0% of <i>Aspergillus tubingensis</i> at ≤4 mg/L, the CLSI wild-type cutoff value for <i>A niger</i>. Voriconazole, itraconazole, and posaconazole showed similar activity to isavuconazole against most cryptic species. Isavuconazole exhibited potent in vitro activity against non-AFM; however, the activity of triazoles varies among and within cryptic species.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae532"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528510/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Forum Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ofid/ofae532","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The activity of isavuconazole and other triazoles against non-fumigatus (non-AFM) Aspergillus causing invasive aspergillosis was evaluated. A total of 390 non-AFM isolates were collected (1/patient) in 2017-2021 from 41 hospitals. Isolates were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry and/or internal spacer region/β-tubulin sequencing and tested by Clinical and Laboratory Standards Institute (CLSI) broth microdilution. CLSI epidemiological cutoff values were applied, where available. Isavuconazole showed activity against Aspergillus sections Flavi (n = 122; minimum inhibitory concentration [MIC]50/90, 0.5/1 mg/L), Terrei (n = 57; MIC50/90, 0.5/0.5 mg/L), Nidulantes (n = 34; MIC50/90, 0.12/0.25 mg/L), Versicolores (n = 7; MIC50, 1 mg/L), and Circumdati (n = 2; MIC range, 0.12-2 mg/L). Similar activity was displayed by other triazoles against those Aspergillus sections. Most of the isolates from Aspergillus sections Fumigati (n = 9), Nigri (n = 146), and Usti (n = 12) exhibited elevated MIC values to isavuconazole (MIC50/90, 2/-, 2/4, and 2/8 mg/L), voriconazole (MIC50/90, 2/-, 1/2, and 4/8 mg/L), itraconazole (MIC50/90, 2/-, 2/4, and 8/>8 mg/L), and posaconazole (MIC50/90, 0.5/-, 0.5/1, and >8/>8 mg/L), respectively. Isavuconazole was active (MIC values, ≤1 mg/L) against Aspergillus parasiticus, Aspergillus tamarii, Aspergillus nomius, Aspergillus nidulans, Aspergillus unguis, Aspergillus terreus, Aspergillus alabamensis, and Aspergillus hortai, while isavuconazole MIC values between 2 and 8 mg/L were observed against cryptic isolates from Aspergillus section Fumigati. Isavuconazole inhibited 96.1% of Aspergillus niger and 80.0% of Aspergillus tubingensis at ≤4 mg/L, the CLSI wild-type cutoff value for A niger. Voriconazole, itraconazole, and posaconazole showed similar activity to isavuconazole against most cryptic species. Isavuconazole exhibited potent in vitro activity against non-AFM; however, the activity of triazoles varies among and within cryptic species.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估三唑类药物对 SENTRY 计划中测试的非烟曲霉和引起侵袭性感染的隐蔽曲霉菌种的活性。
评估了异武康唑和其他三唑类药物对引起侵袭性曲霉病的非烟曲霉(非AFM)的活性。2017-2021年,从41家医院共收集到390株非AFM分离株(1株/患者)。分离物通过基质辅助激光解吸电离飞行时间质谱和/或内部间隔区/β-管蛋白测序进行鉴定,并通过临床和实验室标准协会(CLSI)肉汤微稀释法进行检测。如有 CLSI 流行病学临界值,则采用该临界值。异唑康唑对以下曲霉菌群具有活性:Flavi(n = 122;最低抑菌浓度 [MIC]50/90,0.5/1 mg/L)、Terrei(n = 57;MIC50/90,0.5/0.5 mg/L)、Nidulantes(n = 34;MIC50/90,0.12/0.25 mg/L)、Versicolores(n = 7;MIC50,1 mg/L)和Circumdati(n = 2;MIC范围,0.12-2 mg/L)。其他三唑类药物对这些曲霉菌也显示出类似的活性。来自 Fumigati(n = 9)、Nigri(n = 146)和 Usti(n = 12)曲霉菌群的大多数分离物对异唑醇的 MIC 值升高(MIC50/90、MIC50/90/90、MIC50/90/90、MIC50/90/90、MIC50/90/90、MIC50/90/90、MIC50/90/90 和 MIC50/90/90)、2/-、2/4 和 2/8 mg/L)、伏立康唑(MIC50/90、2/-、1/2 和 4/8 mg/L)、伊曲康唑(MIC50/90、2/-、2/4 和 8/>8 mg/L)和泊沙康唑(MIC50/90、0.5/-、0.5/1 和 >8/>8 mg/L)。异武康唑对寄生曲霉、塔马曲霉、诺米曲霉、尼杜兰曲霉、unguis 曲霉、赤曲霉、阿拉巴马曲霉和霍泰曲霉具有活性(MIC 值≤1 毫克/升),而异武康唑对来自 Fumigati 曲霉科的隐性分离菌的 MIC 值在 2 至 8 毫克/升之间。在≤4 毫克/升(CLSI 对黑曲霉的野生型临界值)的条件下,异唑康唑对 96.1%的黑曲霉和 80.0%的管曲霉具有抑制作用。伏立康唑、伊曲康唑和泊沙康唑对大多数隐居物种的活性与异武康唑相似。异武康唑对非黑僵菌具有很强的体外活性;不过,三唑类药物的活性在不同隐性物种之间和隐性物种内部存在差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Open Forum Infectious Diseases
Open Forum Infectious Diseases Medicine-Neurology (clinical)
CiteScore
6.70
自引率
4.80%
发文量
630
审稿时长
9 weeks
期刊介绍: Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.
期刊最新文献
Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine Landscape. Correction to: Prevalence and factors associated with Aspergillus galactomannan antigenemia among People Living with Advanced HIV Disease in Uganda. Assessment of Antimicrobial Transition Errors from Hospitals to Skilled Nursing Facilities. HIV Preexposure Prophylaxis Utilization and Reasons for Never Using Preexposure Prophylaxis Among Transfeminine Persons in the United States: Findings From the Transgender Women's Internet Survey and Testing (TWIST) Study. Leptospirosis Incidence at Four Sites in Sub-Saharan Africa and South East Asia: An International Multi-Site Hybrid Surveillance Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1